Search

Displaying results 741 - 750 of 3180 in total
  1. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes

  2. Drug

    PF-06882961

    go.drugbank.com/drugs/DB16043
    Investigational

    PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

  3. Drug

    Flumazenil

    go.drugbank.com/drugs/DB01205
    ApprovedInvestigational

    Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversi...

  4. Drug

    Alvimopan

    go.drugbank.com/drugs/DB06274
    ApprovedInvestigational

    Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.

  5. Drug

    MMDA

    go.drugbank.com/drugs/DB01442
    ExperimentalIllicit

    MMDA, or 3-methoxy-4,5-methylenedioxyamphetamine, is a member of the amphetamine drug class with stimulant and psychedelic properties. It also acts as an entheogen and an entactogen. MMDA bears resemblance to the psychopharmacologically ...

  6. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by ...

  7. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

    Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Orciprenaline

    go.drugbank.com/drugs/DB00816
    Approved

    A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

  9. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of ...

    Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors
  10. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    low pH levels. … Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors